Bernstein Liebhard LLP Partner Christian Siebott and Associate Gabriel Galletti co-authored a recent article appearing in the February 2011 edition of the Securities Litigation Report, entitled “The Supreme Court Grapples with the Concerns of Pharmaceutical Companies & Their Investors at Oral Argument in Matrixx.” The article discusses the oral argument in Matrixx Initiatives, Inc. v. Siracusano, No. 09-1156, argued January 10, 2011, in which this issue was presented: “Whether a plaintiff can state a claim under §10(b) of the Securities Exchange Act and SEC Rule 10b-5 based on a pharmaceutical company’s nondisclosure of adverse event reports even though the reports are not alleged to be statistically significant.”
A copy of the article is available here.
